The Effect of Intermittent IL-2 Therapy on CD4 T Cells in the Gut in HIV-1Infected Patients

Read, Sarah W MD, MHS*; Ciccone, Emily J MPH†; Mannon, Peter J MD‡; Yao, Michael D MD§; Chairez, Cheryl L RN, BSN†; Davey, Richard T MD†; Kovacs, Joseph A MD‖; Sereti, Irini MD, MHS†

JAIDS Journal of Acquired Immune Deficiency Syndromes:
doi: 10.1097/QAI.0b013e31820bf84c
Brief Report: Clinical Science

We sought to determine the effects of interleukin-2 administered in combination with antiretroviral therapy (ART) on CD4+ T cells in the gut. Lymphocytes from whole blood, colon, and terminal ileum of HIV-infected adults treated with interleukin-2 and ART or ART alone were examined. There were no differences between groups in the proportion of CD4+ T cells or in expression of CD25 or Ki67 by CD4+ T cells in the gut. Although IL-2 administration leads to expansion of peripheral blood CD4+ T cells, there is no alteration in the proportion or activation of CD4+ T cells in the gut mucosa.

Author Information

From the *Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; †Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; ‡Division of Gastroenterology and Hepatology, University of Alabama-Birmingham, Birmingham, AL; §Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, Bethesda, MD; and ‖Critical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, MD.

Received for publication September 10, 2010; accepted December 15, 2010.

Supported in part by the Intramural Program of the NIH, NIAID, and Critical Care Medicine Department. Additionally, this project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E.

Presented in abstract form at the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia, July 2007.

The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government.

The US government has been granted a use patent for intermittent IL-2 therapy, including J.A.K. as an inventor.

Correspondence to: Sarah W. Read, MD, MHS, 6700B Rockledge Drive, Room 5100, Bethesda, MD 20892 (e-mail:

© 2011 Lippincott Williams & Wilkins, Inc.